Itchbil-M Tablet is a combination medication containing Bilastine 20mg and Montelukast 10mg, formulated for the management of allergic conditions. Bilastine is a second-generation antihistamine that selectively antagonizes peripheral H1 histamine receptors, effectively alleviating symptoms such as pruritus, urticaria, and allergic rhinitis without causing significant sedation. Montelukast is a leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor CysLT1, thereby reducing inflammation, bronchoconstriction, and mucus production associated with allergic responses. The synergistic action of these two agents provides comprehensive relief from allergic manifestations, including chronic urticaria, seasonal allergic rhinitis, and asthma-related symptoms. Itchbil-M is indicated for patients requiring both antihistaminic and anti-inflammatory effects to control persistent allergic symptoms unresponsive to monotherapy. The tablet should be administered orally, once daily, preferably in the evening, with or without food. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with known hypersensitivity to either component. Common adverse effects may include headache, gastrointestinal discomfort, and fatigue. Itchbil-M offers an effective therapeutic option for improving quality of life in patients suffering from allergic disorders by targeting multiple pathogenic pathways.